Back to Research Home
KNSAKiniksa Pharmaceuticals Ltd
Health Care · Biotechnology: Pharmaceutical Preparations · Mid
$76.73−5.03%
As of 23 Oct 2026Mkt cap $6.2B
Stage 13
AVOID
Fundamentals
36.8/75
Technical
5.9/15
Independent
42.7/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +1.8%
- 3M
- +20.8%
- 6M
- +79.3%
- 1Y
- +97.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 79.1xHist median 73.7x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 33.1x
- FCF yield
- 3.0%
Quality
- ROIC
- 15.2%
- Operating margin
- -9.3%
- FCF margin
- 20.1%
- Current ratio
- 3.8x
Growth
- Revenue growth
- +60.1%Latest FY YoY
- Revenue CAGR
- +104.8%
- EPS CAGR
- +93.6%
- FCF CAGR
- —
Capital
- Share-count trend
- +4.8%3Y annualised
- Net cash
- $156M-1.1x OCF
Annual trend
- CAGR 2021–2025
- +104.8%
- Latest · 2025
- $1B
- YoY
- +60.1%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-27
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded